CYTH

Cyclo Therapeutics, Inc. [CYTH] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CYTH Stock Summary

In the News

CYTH Financial details

Company Rating
-
Market Cap
36.18M
Income
-20.06M
Revenue
1.08M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.25
Forward P/E
-
PEG
0.45
P/S
35.64
P/B
-22.92
P/C
-
P/FCF
-2.32
Quick Ratio
0.32
Current Ratio
0.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.31
EPS next Y
-
EPS next Q
-
EPS this Y
-32.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-29.55%
Revenue last 5Y
1.34%
Revenue Q/Q
-37.15%
EPS Q/Q
-20.69%
-
-
-
-
SMA20
-17.86%
SMA50
4.55%
SMA100
-9.21%
Inst Own
-
Inst Trans
-
ROA
-343%
ROE
3430%
ROC
18.9%
Gross Margin
91%
Oper. Margin
-2036%
Profit Margin
-2020%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-2.57
52W High
-
52W Low
-
RSI
47.9
Rel Volume
-
Avg Volume
111.05K
Volume
Perf Week
10.86%
Perf Month
-22.52%
Perf Quarter
-
Perf Half Y
-3.28%
-
-
-
-
Beta
-0.152
-
-
Volatility
0.02%, 0.1%
Prev Close
0%
Price
0.7206
Change
0%

Something similar

Top by Market Cap
V
AMZ.DE
AAPL
NVD.DE
VTSAX
Same Sector
MDG1.DE
IQAI.L
000950.SZ
AQST
JAGX
Same Price Range
TNYA
TELA
MESA
2001.HK
87001.HK
Similar Market Cap
RESE
MWB.DE
DMRL
MLCMG.PA
KPLT

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 111.05K
  • Market Capitalization 36.18M
  • Employee 8
  • CEO Mr. N. Scott Fine
  • Headquarters Gainesville,FL,US
  • IPO Date 2000-05-03
  • Website https://www.cyclotherapeutics.com

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.